Medscheme released updated MEDICINE EXCLUSION LIST APRIL 2023
Some items listed as REQUIRING PRE-AUTHORISATION:
- Forxiga (Dapagliflozin)
- Byetta (Exenatide)
- Janumet (Metformin/Sitagliptin)
- Onglyza (Saxagliptin)
- Januvia (Sitagliptin)
- Galvus (Vildagliptin) + including Metformin combinations
- Liptruzet (Atorvastatin/Ezetimibe)
- Ezetrol (Ezetimibe)
- Inegy(Ezetimibe/Simvastatin)
Details regarding the EXCLUDED ITEMS:
- Trulicity (Dulaglutide)
- Jardiance (Empagliflozin)
- Xultophy (Insulin Degludec and Liraglutide)
- Soliqua (Insulin Glargine and Lixisenatide)
- Victoza (Liraglutide)
- Synjardy (Metformin and Empagliflozin)
- Ozempic (Semaglutide)
Recent Posts
Ending Unproven Fertility Treatments: NICE Calls for Evidence-Based Care in Clinics
Unproven fertility treatments—a term referring to add-on procedures without robust clinical evidence—have come under renewed scrutiny in the UK. Many prospective parents want to know: Why are unproven fertility treatments being discouraged, and what does this mean for fertility clinic choices...
Evolving Strategies in Type 2 Diabetes Management: NICE Guideline Update 2025
Type 2 diabetes management in adults is undergoing significant changes with the draft 2025 NICE guideline update. What are the main improvements in medication, monitoring, and patient care for adults with type 2 diabetes? The answer: The new NICE recommendations prioritize a broader use of SGL...
Unlocking Self-Care South Africa: Strategies and Challenges in Healthcare Reform
The recent interview with Nicola Brink, CEO of the Self-Care Association of South Africa, published by Executive Forecast, highlights both the systemic challenges and transformative opportunities within the country’s self-care South Africa sector. The article details persistent regulatory delays—...